Diaceutics (GB:DXRX)
LSE:DXRX
Want to see GB:DXRX full AI Analyst Report?
DXRX Stock Chart & Stats
161.50 p
0.50 p(0.34%)
At close: 4:00 PM EST
161.50 p
0.50 p(0.34%)
Day’s Range― - ―
52-Week Range112.25 p - 180.00 p
Previous CloseN/A
Volume29.93K
Average Volume (3M)79.63K
Market Cap
£122.59M
Enterprise Value114.83M
Total Cash (Recent Filing)£7.34M
Total Debt (Recent Filing)£1.15M
Price to Earnings (P/E)1335.6
Beta0.58
Next Earnings
Sep 29, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding84,922,280
10 Day Avg. Volume58,068
30 Day Avg. Volume79,634
Financial Highlights & Ratios
PEG Ratio-10.54
Price to Book (P/B)2.67
Price to Sales (P/S)2.82
P/FCF Ratio75.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£216.00Price Target Upside33.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£46.32M
Bulls Say, Bears Say
Bulls Say
Contract NegotiationDiaceutics has successfully renegotiated its first PMx contract with the new commercial licensee, which is worth £4.5m in recurring service revenues.
Revenue GrowthAnother year of strong organic revenue growth in FY24 (+36% to £32.2m) and continued momentum into the first four months of 2025 (+35% to £8.4m), puts the business well on track to deliver on current revenue (+25%) and EBITDA expectations for FY25.
Strategic PartnershipsDiaceutics now works with 18 of the top 20 global pharma companies across 56 therapeutic brands, and during FY24 Diaceutics worked with 85 therapies across 52 customers.
Bears Say
Share Price VolatilityAnalyst sees the recent share pullback as a buying opportunity due to the business delivering very strong organic growth and trading on just 2.3x current FY25E EV/sales, despite its superior top-line growth.
Diaceutics News
DXRX FAQ
What was Diaceutics’s price range in the past 12 months?
Diaceutics lowest share price was 112.25 p and its highest was 180.00 p in the past 12 months.
What is Diaceutics’s market cap?
Diaceutics’s market cap is £122.59M.
When is Diaceutics’s upcoming earnings report date?
Diaceutics’s upcoming earnings report date is Sep 29, 2026 which is in 117 days.
How were Diaceutics’s earnings last quarter?
Diaceutics released its earnings results on May 26, 2026. The company reported 0.03 p earnings per share for the quarter, the consensus estimate of 0.03 p by 0 p.
Is Diaceutics overvalued?
According to Wall Street analysts Diaceutics’s price is currently Undervalued.
Does Diaceutics pay dividends?
Diaceutics does not currently pay dividends.
What is Diaceutics’s EPS estimate?
Diaceutics’s EPS estimate is -0.03.
How many shares outstanding does Diaceutics have?
Diaceutics has 84,922,280 shares outstanding.
What happened to Diaceutics’s price movement after its last earnings report?
Diaceutics reported an EPS of 0.03 p in its last earnings report, expectations of 0.03 p. Following the earnings report the stock price went down -9.309%.
Which hedge fund is a major shareholder of Diaceutics?
Currently, no hedge funds are holding shares in GB:DXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Diaceutics
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX patient journey that enables pharma customers to complete a longitudinal analysis of biomarker testing journeys of individual patients, which identifies opportunities for earlier testing and treatment; DXRX lab benchmarking that enables laboratories to gain competitive edge and compare key criteria to others in the industry providing metrics, such as disease, testing and methodology, market share, turnaround time, and laboratory leadership in these areas; DXRX test reimbursement, which enables pharma customers to engage with laboratories to fund the introduction of novel companion diagnostics, as well as reducing the lag time in test adoption; and DXRX test signal that delivers a real-time alert of a testing event, which allows pharma customers to identify therapeutically actionable patients in the previous weeks. In addition, it offers diagnostic landscape, planning, implementation, and tracking services; and consulting services for precision medicine diagnostics. Further, the company provides test standardization, test quality assessment, test report optimization, laboratory tech support, test access and reimbursement, laboratory training, and educational resources services. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.
DXRX Company Deck
DXRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a mix of positive developments, particularly with revenue growth, high gross margins, and the strategic launch of the PMx solution, alongside record order book figures. However, challenges such as the increased EBITDA loss and decreased TCV were noted. The overall sentiment leans towards optimism, driven by strategic advancements and strong financial positioning.View all GB:DXRX earnings summariesDXRX Stock 12 Month Forecast
Average Price Target
216.00 p
▲(33.75% Upside)
Technical Analysis
Options Prices
Currently, No data available
---